Tempus AI, Inc. (TEM)
NASDAQ: TEM · Real-Time Price · USD
47.03
+1.81 (4.00%)
At close: Apr 1, 2026, 4:00 PM EDT
44.81
-2.22 (-4.72%)
Pre-market: Apr 2, 2026, 9:20 AM EDT
Tempus AI Revenue
In the year 2025, Tempus AI had annual revenue of $1.27B with 83.41% growth. Tempus AI had revenue of $367.21M in the quarter ending December 31, 2025, with 82.98% growth.
Revenue (ttm)
$1.27B
Revenue Growth
+83.41%
P/S Ratio
6.61
Revenue / Employee
$334,681
Employees
3,800
Market Cap
8.41B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.27B | 578.39M | 83.41% |
| Dec 31, 2024 | 693.40M | 161.58M | 30.38% |
| Dec 31, 2023 | 531.82M | 211.15M | 65.85% |
| Dec 31, 2022 | 320.67M | 62.82M | 24.36% |
| Dec 31, 2021 | 257.85M | 69.85M | 37.15% |
| Dec 31, 2020 | 188.00M | 125.95M | 202.95% |
| Dec 31, 2019 | 62.06M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BrightSpring Health Services | 12.91B |
| Veeva Systems | 3.20B |
| Privia Health Group | 2.12B |
| HealthEquity | 1.31B |
| Omnicell | 1.18B |
| Waystar Holding | 1.10B |
| 10x Genomics | 642.82M |
| Doximity | 637.78M |
TEM News
- 23 hours ago - Tempus AI Stock Jumps, ALERT Trial Results Boost EHR Automation Buzz - Benzinga
- 1 day ago - Tempus and Medtronic Announce ALERT Trial Results Showing AI-Driven EHR Notifications Improve Treatment for Significant Valvular Heart Disease - Business Wire
- 2 days ago - Tempus AI: An Attractive Entry Point At Current Prices - Seeking Alpha
- 16 days ago - Tempus and Blood Cancer United® Announce Collaboration to Develop One Of the Largest Pediatric Acute Myeloid Leukemia Real-World Data Registries - Business Wire
- 21 days ago - Why Tempus AI Stock Is Up Wednesday? - Benzinga
- 22 days ago - Tempus Announces Study Highlighting the Role of Advanced Genomic Profiling Features in Identifying Clinically Actionable Findings - Business Wire
- 4 weeks ago - Tempus AI, Inc. (TEM) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript - Seeking Alpha
- 4 weeks ago - AI-Powered Tempus Inks New Multi-Year Merck Deal - Benzinga